Navigation Links
Watson Confirms Rapamune(R) Patent Challenge
Date:4/28/2010

MORRISTOWN, N.J., April 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, has been sued by Pfizer Inc. and Wyeth Pharmaceuticals Inc. in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for sirolimus tablets in the 1 mg and 2 mg strengths. Watson's ANDA is for a generic equivalent of Wyeth's Rapamune® tablets product. The suit was filed on April 28, 2010 in the United States District Court for the District of Delaware.

Pursuant to the Hatch-Waxman Act, Watson previously notified Pfizer and Wyeth that Watson's ANDA contains a paragraph IV certification asserting that U.S. Patent No. 5,100,899 is invalid, unenforceable and /or will not be infringed by the commercial manufacture, use or sale of the drug products described in Watson's ANDA.  Based on available information, Watson believes it may be a "first applicant" to file an ANDA for the 1 mg and 2 mg generic version of Rapamune® and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity for those strengths.

Rapamune® (sirolimus) tablets are indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants.  For the twelve months ending February 2010, Rapamune® had total U.S. sales of approximately $210.5 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts and FDA approvals or actions, if any; the difficulty of predicting the timing or outcome of litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report for the year ended December 31,2009. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Rapamune® is a registered trademark of Pfizer Inc.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms Cenestin(R) Patent Challenge
2. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
3. Watson to Present at Barclays 2010 Global Healthcare Conference
4. Watson Receives FDA Approval for Generic Cardizem(R) LA
5. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
6. Watson Announces Actos(R) Patent Challenge Settlement
7. Watson Confirms Filing of Generic Opana(R) ER Application
8. Watson Signs Agreement to Divest Equity Interest in ScinoPharm
9. Watson to Present at CLSA/Asia USA Investors Forum
10. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
11. Watson Completes Acquisition of Eden Biodesign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Ariz. , May 3, 2016  As a ... twice contracted rheumatic fever, which damaged his heart. He ... But by June 2013, Shepherd,s heart was giving ... from death. On June 20, 2013, the ... Total Artificial Heart (TAH-t). Like a heart transplant, the ...
(Date:5/3/2016)... OSWEGO, Ore. , May 3, 2016 /PRNewswire/ ... endovascular medical technology, today announced Food and Drug ... cardiac resynchronization defibrillator that provides heart failure patients ... scans. Iperia devices also have remote monitoring with ... that adapts the heart rate in response to ...
(Date:5/3/2016)... May 3, 2016   BIOTRONIK will be ... care beyond the implant at the Heart Rhythm Society,s ... San Francisco . ... highest quality of patient care and satisfaction possible. Part ... each and every tomorrow," said Marlou Janssen , ...
Breaking Medicine Technology:
(Date:5/4/2016)... Carlsbad, CA (PRWEB) , ... May 04, 2016 , ... ... has recently partnered with local company MitoXcell in preparation of the launch of her ... day jump start plan is a nutritional guide designed to jump start a new ...
(Date:5/4/2016)... ... May 04, 2016 , ... The preeminent surgical aftercare ... Dickinson needed following breast cancer surgery. In March 2016, the 61-year-old model and reality ... breast cancer that occurs in the milk ducts, according to an interview with ...
(Date:5/4/2016)... ... ... Advanced Spine & Sport Medical Rehabilitation Center, which is renowned for its ... seminar on stem cell injections. The seminar is scheduled for Wednesday, May 18, from ... Suite 110, Ventura, CA. There are only 10 seats available. , “The purpose ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... and support for knees, ankles, and elbows. Engineered with athletes in mind, ... flat-bed manufacturing (opposed to ineffective circular knitting, common in the industry) produces ...
(Date:5/4/2016)... , ... May 03, ... manufacturer of innovative infant and child products, today revealed the non-toxic ... ability to help babies deal with teething pain is just part ... no toxic gels, and are BPA-, PVC-, and phthalate-free. , ...
Breaking Medicine News(10 mins):